1 active not recruiting, 1 recruiting, 1 terminated, 1 withdrawn. 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Not applicable | 1 | Recruiting 1 |
Follow AIDS-related Lymphoma: new trials by email Literature Review of AIDS-related Lymphoma trials Research Report on AIDS-related Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma Oral Antiretroviral Therapy, albuvirtide, Cabotegravir/Rilpivirine - AIDS-related Lymphoma, HIV Infection | Not applicable | Recruiting | Shanghai Public Health Clinical Center | 60 | 2026-05-26 | 2026-07-27 |
| Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 46 | 2018-03-16 | 2026-08-11 |
| High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC) - AIDS-related Lymphoma, HIV Infections | Phase 1 / Phase 2 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 5 | 2008-11-28 | 2022-09-08 |
| Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma cisplatin, cytarabine, etoposide - AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma | Phase 2 | Withdrawn | AIDS Malignancy Consortium | 2006-02-01 | 2016-02-03 |
Lymphoma, AIDS-Related (4) · HIV Infections (2) · Acquired Immunodeficiency Syndrome (1) · Burkitt Lymphoma (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Large-Cell, Immunoblastic (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma, B-Cell (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Infections (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Virus Diseases (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2)
Etoposide (2) · Rituximab (2) · Antibodies, Monoclonal (1) · Biological Therapy (1) · CT-P10 (1) · Cisplatin (1) · Cyclophosphamide (1) · Cytarabine (1) · Doxorubicin (1) · Drug Therapy (1) · Filgrastim (1) · Genes (1) · Granulocyte Colony-Stimulating Factor (1) · Immunization, Passive (1) · Methylprednisolone (1)
AIDS Malignancy Consortium (1) · National Cancer Institute (NCI) (1) · Shanghai Public Health Clinical Center (1) · Universitätsklinikum Hamburg-Eppendorf (1)
China (1) · Germany (1) · United States (1)
Alexandra M. Levine, MD (1) · Anil Tulpule, MD (1) · Ida C Wong-Sefidan (1) · Nicolaus Kroeger (1)
PMID 21289631, PMID 38427337, PMID 41429707
UM1CA121947 (1)